OptiNose, Inc. (OPTN:NASDAQ) Annual Reports & Investor Relations Material

Overview

OptiNose, Inc. is a pharmaceutical company with a keen focus on developing and commercializing products exclusively for patients receiving treatment by ear, nose, throat, and allergy specialists in the US. Its proprietary exhalation delivery system (EDS), XHANCE, is designed to deliver a corticosteroid acting topically in treating chronic rhinosinusitis with nasal polyps. OptiNose is also in a Phase IIIb clinical trial for the treatment of chronic sinusitis. Another product in its portfolio is Onzetra Xsail, which is a powder EDS device. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail, besides partnering with Orexia Therapeutics to develop, manufacture, import, and sell products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. Established in 2000, OptiNose is headquartered in Yardley, Pennsylvania.

Frequently Asked Questions

What is OptiNose, Inc.'s ticker?

OptiNose, Inc.'s ticker is OPTN

What exchange is OptiNose, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are OptiNose, Inc.'s headquarters?

They are based in Yardley, Pennsylvania

How many employees does OptiNose, Inc. have?

There are 201-500 employees working at OptiNose, Inc.

What is OptiNose, Inc.'s website?

It is https://www.optinose.com/

What type of sector is OptiNose, Inc.?

OptiNose, Inc. is in the Healthcare sector

What type of industry is OptiNose, Inc.?

OptiNose, Inc. is in the Drug Manufacturers - Other industry

Who are OptiNose, Inc.'s peers and competitors?

The following five companies are OptiNose, Inc.'s industry peers:

- Lannett Company

- AbbVie

- The Flowr Corporation

- Durect Corp.

- Diurnal Group plc